BioCentury | Jan 25, 2021
Product Development

Merck shifts COVID-19 focus to therapeutics after discontinuing vaccines

...with the full dataset coming by May. MK-7110, which Merck gained through its $425 million acquisition of OncoImmune Inc. in...
BioCentury | Dec 22, 2020
Product Development

Dec. 21-23 COVID-19 roundup: U.S. secures 100M more doses of Pfizer-BioNTech vaccine; plus Merck, BioCryst, CureVac, NIH and Sputnik V

...treat patients with severe and critical COVID-19. Merck gained the program through its $425 million takeout of OncoImmune Inc. last...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

...By Virginia Li, Associate Editor OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid...
...which includes undisclosed milestones and royalties, Merck & Co. Inc. (NYSE:MRK) will gain lead candidate CD24Fc. OncoImmune Inc....
...September, after raising a $56 million series B round to fund its late stage studies, OncoImmune...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...By BC Staff OncoImmune raises $56M series BOncoImmune Inc. raised $56 million in a series B...
...Wisconsin. Completion is expected by mid-2022. TARGETSCB1 (CNR1) – Cannabinoid receptor 1CD47FAK – Focal adhesion kinase BC Staff OncoImmune Inc. Inversago...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

...is now $56.45 (see "Updated Data Bring NextCure Back to Earth" ). Other companies, including OncoImmune Inc....
...opposite direction, co-opting SIGLEC ligands to develop immune-tolerizing therapies for diseases driven by excess inflammation. OncoImmune's...
...human tissue samples. The SIGLEC10/CD24 axis is also gaining traction as a therapeutic target, beyond OncoImmune's...
BioCentury | Jan 13, 2017
Financial News

OncoImmune raises $15M in series A

...a recombinant fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain. OncoImmune...
...for autoimmune disorders, cancer or GvHD. The company did not respond to inquiries. Last year, OncoImmune...
...to ONC-392 , a preclinical cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152) inhibitor. OncoImmune...
BioCentury | Jan 13, 2017
Financial News

OncoImmune completes venture financing

...million in a series A round led by 3E Bioventures Capital. OncoImmune Inc. , Rockville, Md. Alex Himes OncoImmune Inc....
BioCentury | Sep 19, 2016
Company News

OncoImmune, Pfizer deal

...against cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ), and additional anti-CTLA4 antibodies. OncoImmune...
...said it plans to evaluate ONC-392 in immuno-oncology. The companies declined to provide additional details. OncoImmune Inc....
BioCentury | Sep 15, 2016
Company News

Pfizer, OncoImmune in deal for preclinical CTLA-4 mAb

...to ONC-392, a preclinical cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ) inhibitor. OncoImmune...
BioCentury | Dec 8, 2003
Company News

OncoImmune Ltd. other research news

...of the disease. The authors suggested CD24 could be a useful target for treating MS. OncoImmune...
Items per page:
1 - 10 of 11
BioCentury | Jan 25, 2021
Product Development

Merck shifts COVID-19 focus to therapeutics after discontinuing vaccines

...with the full dataset coming by May. MK-7110, which Merck gained through its $425 million acquisition of OncoImmune Inc. in...
BioCentury | Dec 22, 2020
Product Development

Dec. 21-23 COVID-19 roundup: U.S. secures 100M more doses of Pfizer-BioNTech vaccine; plus Merck, BioCryst, CureVac, NIH and Sputnik V

...treat patients with severe and critical COVID-19. Merck gained the program through its $425 million takeout of OncoImmune Inc. last...
BioCentury | Nov 24, 2020
Deals

OncoImmune's choice to repurpose GvHD program for COVID pays off via $425M takeout by Merck

...By Virginia Li, Associate Editor OncoImmune’s move to repurpose its GvHD program for COVID-19 has paid...
...which includes undisclosed milestones and royalties, Merck & Co. Inc. (NYSE:MRK) will gain lead candidate CD24Fc. OncoImmune Inc....
...September, after raising a $56 million series B round to fund its late stage studies, OncoImmune...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...By BC Staff OncoImmune raises $56M series BOncoImmune Inc. raised $56 million in a series B...
...Wisconsin. Completion is expected by mid-2022. TARGETSCB1 (CNR1) – Cannabinoid receptor 1CD47FAK – Focal adhesion kinase BC Staff OncoImmune Inc. Inversago...
BioCentury | Jan 4, 2020
Targets & Mechanisms

SIGLECs go from homing beacons to next-generation checkpoints

...is now $56.45 (see "Updated Data Bring NextCure Back to Earth" ). Other companies, including OncoImmune Inc....
...opposite direction, co-opting SIGLEC ligands to develop immune-tolerizing therapies for diseases driven by excess inflammation. OncoImmune's...
...human tissue samples. The SIGLEC10/CD24 axis is also gaining traction as a therapeutic target, beyond OncoImmune's...
BioCentury | Jan 13, 2017
Financial News

OncoImmune raises $15M in series A

...a recombinant fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain. OncoImmune...
...for autoimmune disorders, cancer or GvHD. The company did not respond to inquiries. Last year, OncoImmune...
...to ONC-392 , a preclinical cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152) inhibitor. OncoImmune...
BioCentury | Jan 13, 2017
Financial News

OncoImmune completes venture financing

...million in a series A round led by 3E Bioventures Capital. OncoImmune Inc. , Rockville, Md. Alex Himes OncoImmune Inc....
BioCentury | Sep 19, 2016
Company News

OncoImmune, Pfizer deal

...against cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ), and additional anti-CTLA4 antibodies. OncoImmune...
...said it plans to evaluate ONC-392 in immuno-oncology. The companies declined to provide additional details. OncoImmune Inc....
BioCentury | Sep 15, 2016
Company News

Pfizer, OncoImmune in deal for preclinical CTLA-4 mAb

...to ONC-392, a preclinical cytotoxic T-lymphocyte associated protein 4 ( CTLA4 ; CD152 ) inhibitor. OncoImmune...
BioCentury | Dec 8, 2003
Company News

OncoImmune Ltd. other research news

...of the disease. The authors suggested CD24 could be a useful target for treating MS. OncoImmune...
Items per page:
1 - 10 of 11